TREMFYA

( ARTG ) Plaque Psoriasis,TREMFYA is indicated for the treatment of adult patients (18 years of age or older) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.,TREMFYA is indicated for the treatment of paediatric patients (6 years of age or older) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.,Psoriatic Arthritis,TREMFYA is indicated for the treatment of adult patients with active psoriatic arthritis, who have had an inadequate response to, or are intolerant to prior DMARD therapy.,Ulcerative Colitis,TREMFYA is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy, a biologic treatment, or a Janus kinase (JAK) inhibitor.,Crohns Disease,TREMFYA is indicated for the treatment of adult patients with moderately to severely active Crohns disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic treatment.